Literature DB >> 18398993

FDA approval: maraviroc.

Paul E Sax.   

Abstract

Mesh:

Substances:

Year:  2007        PMID: 18398993

Source DB:  PubMed          Journal:  AIDS Clin Care        ISSN: 1043-1543


× No keyword cloud information.
  5 in total

Review 1.  Anti-HIV drug development through computational methods.

Authors:  Wan-Gang Gu; Xuan Zhang; Jun-Fa Yuan
Journal:  AAPS J       Date:  2014-04-24       Impact factor: 4.009

2.  Blocking HIV-1 entry by a gp120 surface binding inhibitor.

Authors:  Lun K Tsou; Chin-Ho Chen; Ginger E Dutschman; Yung-Chi Cheng; Andrew D Hamilton
Journal:  Bioorg Med Chem Lett       Date:  2012-03-02       Impact factor: 2.823

3.  Frequent CXCR4 tropism of HIV-1 subtype A and CRF02_AG during late-stage disease--indication of an evolving epidemic in West Africa.

Authors:  Joakim Esbjörnsson; Fredrik Månsson; Wilma Martínez-Arias; Elzbieta Vincic; Antonio J Biague; Zacarias J da Silva; Eva Maria Fenyö; Hans Norrgren; Patrik Medstrand
Journal:  Retrovirology       Date:  2010-03-22       Impact factor: 4.602

Review 4.  Functional genomic screening to enhance oncolytic virotherapy.

Authors:  D J Mahoney; D F Stojdl
Journal:  Br J Cancer       Date:  2012-11-20       Impact factor: 7.640

5.  Dual-acting stapled peptides target both HIV-1 entry and assembly.

Authors:  Hongtao Zhang; Francesca Curreli; Abdul A Waheed; Peter Y Mercredi; Mansi Mehta; Pallavi Bhargava; Daniel Scacalossi; Xiaohe Tong; Shawn Lee; Alan Cooper; Michael F Summers; Eric O Freed; Asim K Debnath
Journal:  Retrovirology       Date:  2013-11-15       Impact factor: 4.602

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.